TECVAYLI

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Italy, Lithuania, United States

Active ingredients

The drug TECVAYLI contains one active pharmaceutical ingredient (API):

1 Teclistamab UNII 54534MX6Z9 - TECLISTAMAB

Teclistamab is a full-size, IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA), which is expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. With its dual binding sites, teclistamab is able to draw CD3+ T cells in close proximity to BCMA+ cells, resulting in T cell activation and subsequent lysis and death of BCMA+ cells, which is mediated by secreted perforin and various granzymes stored in the secretory vesicles of cytotoxic T cells. Read about Teclistamab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TECVAYLI Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX24		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3040636, 3040647
Country: FR	Base de données publique des médicaments	Identifier(s): 61368383, 61935054
Country: IT	Agenzia del Farmaco	Identifier(s): 050296019, 050296021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095409, 1095410
Country: US	FDA, National Drug Code	Identifier(s): 57894-449, 57894-450